Advances in Intra-abdominal Sepsis: What Is New?

Zachary C. Dietch, Puja M. Shah, Robert G. Sawyer*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


We have reviewed the literature regarding recent advances in the management of intra-abdominal sepsis, with a focus on antimicrobial agents, duration of therapy, and source control. Several important developments in these areas are discussed in this review. The introduction of a new antimicrobial agent—ceftolozane/tazobactam—marks the first novel agent for treating intra-abdominal infections in a number of years, and its indications for use and supporting evidence are reviewed here. In addition, we discuss recent evidence that clarifies the importance of early source control for intra-abdominal infection and new data that suggests that an abbreviated course of antimicrobial therapy for intra-abdominal infection is equally effective as prolonged therapy.

Original languageEnglish (US)
Article number40
JournalCurrent Infectious Disease Reports
Issue number8
StatePublished - Aug 24 2015
Externally publishedYes


  • Antibiotic
  • Antimicrobial
  • Drainage
  • Duration
  • Intra-abdominal infection
  • Peritonitis
  • Source control

ASJC Scopus subject areas

  • Infectious Diseases


Dive into the research topics of 'Advances in Intra-abdominal Sepsis: What Is New?'. Together they form a unique fingerprint.

Cite this